- Home
- WKSP vs SPRB Comparison
WKSP vs SPRB Comparison
Compare WKSP & SPRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WKSP
- SPRB
- Stock Information
- Founded
- WKSP 2003
- SPRB 2014
- Country
- WKSP United States
- SPRB United States
- Employees
- WKSP N/A
- SPRB N/A
- Industry
- WKSP Auto Parts:O.E.M.
- SPRB Medicinal Chemicals and Botanical Products
- Sector
- WKSP Consumer Discretionary
- SPRB Health Care
- Exchange
- WKSP Nasdaq
- SPRB Nasdaq
- Market Cap
- WKSP 21.3M
- SPRB 22.8M
- IPO Year
- WKSP N/A
- SPRB 2020
- Fundamental
- Price
- WKSP $0.95
- SPRB $0.38
- Analyst Decision
- WKSP
- SPRB Hold
- Analyst Count
- WKSP 0
- SPRB 7
- Target Price
- WKSP N/A
- SPRB $2.17
- AVG Volume (30 Days)
- WKSP 2.8M
- SPRB 870.1K
- Earning Date
- WKSP 11-13-2024
- SPRB 11-11-2024
- Dividend Yield
- WKSP N/A
- SPRB N/A
- EPS Growth
- WKSP N/A
- SPRB N/A
- EPS
- WKSP N/A
- SPRB N/A
- Revenue
- WKSP $6,395,908.00
- SPRB $7,101,000.00
- Revenue This Year
- WKSP $366.78
- SPRB N/A
- Revenue Next Year
- WKSP $311.43
- SPRB N/A
- P/E Ratio
- WKSP N/A
- SPRB N/A
- Revenue Growth
- WKSP 776.97
- SPRB N/A
- 52 Week Low
- WKSP $0.36
- SPRB $0.37
- 52 Week High
- WKSP $1.66
- SPRB $5.95
- Technical
- Relative Strength Index (RSI)
- WKSP 62.36
- SPRB 31.70
- Support Level
- WKSP $0.78
- SPRB $0.37
- Resistance Level
- WKSP $1.09
- SPRB $0.42
- Average True Range (ATR)
- WKSP 0.11
- SPRB 0.04
- MACD
- WKSP 0.03
- SPRB -0.01
- Stochastic Oscillator
- WKSP 69.11
- SPRB 5.93
About WKSP Worksport Ltd.
Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers.
About SPRB Spruce Biosciences Inc.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).